Navigation Links
Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents

Risk of Late Thrombosis is Minimized with Genous Stent

BARCELONA, Spain, May 23, 2007 /PRNewswire/ -- The efficacy of OrbusNeich's Genous(TM) Bio-engineered R stent compares favorably to that of drug-eluting stents, while the risk of late thrombosis is minimized with the Genous stent, according to an interim analysis of post-marketing data presented today by Robbert de Winter, M.D., Ph.D., at EuroPCR 2007 in Barcelona, Spain.

Collected from more than 120 sites in 29 countries, follow-up data for patients who received at least one Genous Bio-engineered R stent show:

    -- For 2,175 patients at 30 days, the target lesion revascularization

       (TLR) rate was 0.05%, the major adverse cardiac events (MACE) rate was

       1.61%, and the sub-acute thrombosis (SAT) rate was 0.37%


    -- For 1,039 patients at six months, the TLR rate was 2.89%, the MACE rate

       was 5.87%, and the thrombosis rate was 0.88%

"The real-world data speak to the promise of OrbusNeich's innovative pro- healing approach with Genous, especially when we compare the findings to those of the drug-eluting stent registries," said de Winter, a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. "The importance of this interim data is that Genous appears to be as effective as drug-eluting stents with only the need for minimal dual-antiplatelet therapy, which is safer for patients and less expensive."

OrbusNeich's e-HEALING is a multi-center, worldwide prospective registry of patients treated with the Genous Bio-engineered R stent in accordance with the instructions for use. The protocol recommends that patients receive two weeks of statin treatment prior to the procedure and one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary outcome of the reg
'"/>




Page: 1 2 3

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
9. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
10. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
11. Studies Show Efficacy and Safety of Alexions Soliris in Broad Population of PNH Patients
Post Your Comments:
(Date:5/27/2015)... DUBLIN , May 27, 2015 /PRNewswire/ ... ) has announced the addition of the  ...   report to their offering.  ... provides a worldwide strategic overview of the ... regions, market segments and product categories. , ...
(Date:5/27/2015)...   Madison Laser Tattoo Removal is the first ... and the surrounding area to offer treatments with the ... Removal is dedicated to bringing a solution to those living ... "I founded Madison Laser Tattoo Removal to give ... skin to its natural look," said Emily Livesey, RN ...
(Date:5/27/2015)... May 27, 2015 PharmaPoint: Type 1 Diabetes - ... Type 1 diabetes (T1D) is an autoimmune disease that ... that the body can no longer produce insulin. Over the ... at present, no other treatment can be offered to a ... insulin analogs with different times of action - long-acting as ...
Breaking Medicine Technology:Global Orthopedics Market Strategies 2015 2Madison Laser Tattoo Removal Brings Superior Laser Tattoo Removal Services To Madison, WI With Astanza Duality 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4
... 2012  InterMune, Inc. (NADSAQ: ITMN) today reported ... announced its decision granting the additional benefit ... treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF).  ... 4 (not quantifiable benefit)  in the rating ...
... March 15, 2012 Reportlinker.com announces that ... in its catalogue: ... http://www.reportlinker.com/p0578259/Vaccines---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This market research report ... actual market situation, trends and future outlook ...
Cached Medicine Technology:Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 2Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 3Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 4Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 5Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 6Vaccines - Asia 2
(Date:5/27/2015)... “ Nursing Homes are starting to supplant hospitals as focus ... recent April 2015 New York Times article. While Americans, in ... 20-plus years of research have documented the risks of hospitalization ... are both safer for older patients and less costly than ... widely, patients and family members may worry whether a nursing ...
(Date:5/27/2015)... IL (PRWEB) May 27, 2015 While ... treat hair loss, a new pilot study conducted by ... Restoration Surgery (ISHRS) has found hair follicle grafting can ... cutting-edge research was partially funded by ISHRS, which offers ... relating to hair restoration. , In the past ...
(Date:5/27/2015)... 27, 2015 The new http://www.carsonenergy.com ... Why investors should consider oil and gas investing, the ... wells are drilled, industry news, IRA investing, definitions and ... years of knowledge and experience is now in one ... to be able to access 24 hours a day, ...
(Date:5/27/2015)... Plainsboro, NJ (PRWEB) May 27, 2015 ... Advocacy Network (BCAN) , whose mission is to advance ... bladder cancer, have joined forces to battle the fifth ... cells in the bladder’s lining start to grow out ... patients and their families at every stage of the ...
(Date:5/27/2015)... Difass USA, a modern supplement brand committed ... first three flagship products, Dormiva™, Relaxiva™ and Reminiva™. All ... http://www.difassusa.com . , A restful night’s sleep is ... people struggle with getting the full amount of sleep ... designed to help you fall asleep and stay asleep, ...
Breaking Medicine News(10 mins):Health News:BestNursingHomes.com Launches on National Senior Health and Fitness Day 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2
... News) -- Prescriptions for opioid painkillers to treat chronic ... between 1997 and 2008, according to a new study. ... clinics is concerning for several reasons, said lead author ... the University of North Carolina Medical School at Chapel ...
... (HealthDay News) -- Racial and ethnic differences in diet, ... socioeconomic status, a new U.S. study suggests. The ... are more likely to be overweight than those with ... They also found that levels of nutritional knowledge and ...
... News) -- Police officers who have to draw or ... feeling powerless, guilty, angry and fearful afterward, Canadian researchers ... for experiencing such traumatic events, police officers are no ... than the general population, according to a new Canadian ...
... , FRIDAY, Dec. 2 (HealthDay News) -- Major depression and ... pregnant women and new mothers, a new study indicates. ... women are and what led up to these tragic events," ... medicine at the University of Michigan Medical School, said in ...
... , This release is available in Portuguese ... Janeiro and Recife, Brazil, and Geneva, Switzerland 2 December ... Partners, Meeting in Rio de Janeiro, Brazil, Dr Carlos Gadelha, ... Health, announced that Brazil,s National Health Surveillance Agency (ANVISA) granted ...
... of Hematology (ASH) announces the recipients of its 2012 ... for fellows and junior faculty pursuing research careers to ... must complete their training and achieve status as an ... and $150,000 for junior faculty over a two- to ...
Cached Medicine News:Health News:Socioeconomic Status Main Predictor of Health Habits: Study 2Health News:Police at No Greater PTSD Risk Than General Public: Study 2Health News:Depression, Partner Conflict Raise Suicide Risk for Pregnant Women, New Moms 2Health News:New child-adapted Chagas disease treatment approved for registration 2Health News:New child-adapted Chagas disease treatment approved for registration 3Health News:The American Society of Hematology announces 2012 Scholar Award winners 2Health News:The American Society of Hematology announces 2012 Scholar Award winners 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: